Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/214
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | SANTOS, Raul D. | - |
dc.contributor.author | WATERS, David D. | - |
dc.contributor.author | TARASENKO, Lisa | - |
dc.contributor.author | MESSIG, Michael | - |
dc.contributor.author | JUKEMA, J. Wouter | - |
dc.contributor.author | CHIANG, Cheng-Wen | - |
dc.contributor.author | FERRIERES, Jean | - |
dc.contributor.author | FOODY, JoAnne M. | - |
dc.date.accessioned | 2013-07-30T14:34:55Z | - |
dc.date.available | 2013-07-30T14:34:55Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | ATHEROSCLEROSIS, v.224, n.1, p.150-153, 2012 | - |
dc.identifier.issn | 0021-9150 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/214 | - |
dc.description.abstract | Objective: This study evaluated the success in attaining non-HDL-cholesterol (non-HDL-C) goals in the multinational L-TAP 2 study. Methods: 9955 patients >= 20 years of age with dyslipidemia on stable lipid-lowering therapy were enrolled from nine countries. Results: Success rates for non-HDL-C goals were 86% in low, 70% in moderate, and 52% in high-risk patients (63% overall). In patients with triglycerides of >200 mg/dL success rates for non-HDL-C goals were 35% vs. 69% in those with <= 200 mg/dL (p < 0.0001). Among patients attaining their LDL-C goal, 18% did not attain their non-HDL-C goal. In those with coronary disease and at least two risk factors, only 34% and 30% attained respectively their non-HDL-C and LDL-C goals. Rates of failure in attaining both LDL-C and non-HDL-C goals were highest in Latin America. Conclusions: Non-HDL-C goal attainment lagged behind LDL-C goal attainment; this gap was greatest in higher-risk patients. | - |
dc.description.sponsorship | Anthera | - |
dc.description.sponsorship | Cortria | - |
dc.description.sponsorship | Genentech | - |
dc.description.sponsorship | Merck/Schering-Plough | - |
dc.description.sponsorship | Pfizer Inc. | - |
dc.description.sponsorship | Astellas | - |
dc.description.sponsorship | AstraZeneca | - |
dc.description.sponsorship | Biotronik | - |
dc.description.sponsorship | Boston Scientific | - |
dc.description.sponsorship | Daiichi Sankyo | - |
dc.description.sponsorship | Lilly | - |
dc.description.sponsorship | Genzyme | - |
dc.description.sponsorship | Medtronic | - |
dc.description.sponsorship | Orbus Neich | - |
dc.description.sponsorship | Novartis | - |
dc.description.sponsorship | Roche | - |
dc.description.sponsorship | Servier | - |
dc.description.sponsorship | Sanofi Aventis | - |
dc.description.sponsorship | Netherlands Heart Foundation | - |
dc.description.sponsorship | Interuniversity Cardiology Institute of the Netherlands | - |
dc.description.sponsorship | European Community Framework KP7 Programme | - |
dc.language.iso | eng | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.relation.ispartof | Atherosclerosis | - |
dc.rights | restrictedAccess | - |
dc.subject | Non-HDL cholesterol | - |
dc.subject | LDL-cholesterol | - |
dc.subject | Coronary heart disease | - |
dc.subject | Risk factors | - |
dc.subject | Triglycerides | - |
dc.subject.other | low-density-lipoprotein | - |
dc.subject.other | cardiovascular-disease | - |
dc.subject.other | task-force | - |
dc.subject.other | guidelines | - |
dc.subject.other | recommendations | - |
dc.subject.other | prevention | - |
dc.subject.other | management | - |
dc.subject.other | risk | - |
dc.subject.other | apolipoproteins | - |
dc.subject.other | dyslipidemia | - |
dc.title | A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2 | - |
dc.type | article | - |
dc.rights.holder | Copyright ELSEVIER IRELAND LTD | - |
dc.identifier.doi | 10.1016/j.atherosclerosis.2012.06.052 | - |
dc.identifier.pmid | 22818564 | - |
dc.subject.wos | Peripheral Vascular Disease | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | WATERS, David D.:San Francisco Gen Hosp, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA | - |
hcfmusp.author.external | TARASENKO, Lisa:Pfizer Inc, New York, NY USA | - |
hcfmusp.author.external | MESSIG, Michael:Pfizer Inc, New York, NY USA | - |
hcfmusp.author.external | JUKEMA, J. Wouter:Leiden Univ, Med Ctr, Leiden, Netherlands | - |
hcfmusp.author.external | CHIANG, Cheng-Wen:Cathay Gen Hosp, Taipei, Taiwan; Taipei Med Univ, Taipei, Taiwan | - |
hcfmusp.author.external | FERRIERES, Jean:Hop Rangueil, Toulouse, France | - |
hcfmusp.author.external | FOODY, JoAnne M.:Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA | - |
hcfmusp.description.beginpage | 150 | - |
hcfmusp.description.endpage | 153 | - |
hcfmusp.description.issue | 1 | - |
hcfmusp.description.volume | 224 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000308078000024 | - |
hcfmusp.origem.id | 2-s2.0-84865388510 | - |
hcfmusp.publisher.city | CLARE | - |
hcfmusp.publisher.country | IRELAND | - |
hcfmusp.relation.reference | Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644 | - |
hcfmusp.relation.reference | Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5 | - |
hcfmusp.relation.reference | Blaha MJ, 2008, J CLIN LIPIDOL, V2, P267, DOI 10.1016/j.jacl.2008.06.013 | - |
hcfmusp.relation.reference | Catapano AL, 2011, ATHEROSCLEROSIS, V217, P3, DOI 10.1016/j.atherosclerosis.2011.06.028 | - |
hcfmusp.relation.reference | Davidson MH, 2005, AM J CARDIOL, V96, P556, DOI 10.1016/j.amjcard.2005.04.019 | - |
hcfmusp.relation.reference | De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6 | - |
hcfmusp.relation.reference | Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993 | - |
hcfmusp.relation.reference | Genest J, 2003, CAN MED ASSOC J, V169, P921 | - |
hcfmusp.relation.reference | Genest J, 2009, CAN J CARDIOL, V25, P567 | - |
hcfmusp.relation.reference | Kastelein JJP, 2008, CIRCULATION, V117, P3002, DOI 10.1161/CIRCULATIONAHA.107.713438 | - |
hcfmusp.relation.reference | National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, NY TIMES 1026, V106, P3143 | - |
hcfmusp.relation.reference | Robinson JG, 2009, J AM COLL CARDIOL, V53, P316, DOI 10.1016/j.jacc.2008.10.024 | - |
hcfmusp.relation.reference | Virani SS, 2011, AM HEART J, V161, P1140, DOI 10.1016/j.ahj.2011.03.023 | - |
hcfmusp.relation.reference | Waters DD, 2009, CIRCULATION, V120, P28, DOI 10.1161/CIRCULATIONAHA.108.838466 | - |
hcfmusp.relation.reference | Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | AstraZeneca | - |
hcfmusp.remissive.sponsorship | Bayer | - |
hcfmusp.remissive.sponsorship | Daiichi | - |
hcfmusp.remissive.sponsorship | Lilly | - |
hcfmusp.remissive.sponsorship | Merck | - |
hcfmusp.remissive.sponsorship | Novartis | - |
hcfmusp.remissive.sponsorship | Pfizer | - |
hcfmusp.remissive.sponsorship | Roche | - |
hcfmusp.remissive.sponsorship | Sanofi-Aventis | - |
hcfmusp.remissive.sponsorship | Servier | - |
hcfmusp.citation.scopus | 35 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCP Artigos e Materiais de Revistas Científicas - HC/InCor |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_SANTOS_A_comparison_of_non_HDL_and_LDL_cholesterol_2012_eng.pdf Restricted Access | publishedVersion (English) | 121.65 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.